(6S)-5,6,7,8-Tetrahydro-6-[propyl[2-(2-thienyl)ethyl]amino]-1-naphthalenol
| Title | Journal |
|---|---|
| Why are most phospholipidosis inducers also hERG blockers? | Archives of toxicology 20171201 |
| Rotigotine transdermal patch for the treatment of Parkinson's Disease. | Fundamental & clinical pharmacology 20130201 |
| Three-month subchronic intramuscular toxicity study of rotigotine-loaded microspheres in Cynomolgus monkeys. | Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 20130201 |
| Dopamine D₂-agonist rotigotine effects on cortical excitability and central cholinergic transmission in Alzheimer's disease patients. | Neuropharmacology 20130101 |
| The powerful pre-treatment effect: placebo responses in restless legs syndrome trials. | European journal of neurology 20121001 |
| ADMET considerations for restless leg syndrome drug treatments. | Expert opinion on drug metabolism & toxicology 20121001 |
| Preparation of rotigotine-loaded microspheres and their combination use with L-DOPA to modify dyskinesias in 6-OHDA-lesioned rats. | Pharmaceutical research 20120901 |
| In brief: transdermal rotigotine (Neupro). | The Medical letter on drugs and therapeutics 20120820 |
| The effects of the dopamine agonist rotigotine on hemispatial neglect following stroke. | Brain : a journal of neurology 20120801 |
| Long-term safety and tolerability of rotigotine transdermal system in patients with early-stage idiopathic Parkinson's disease: a prospective, open-label extension study. | Parkinsonism & related disorders 20120601 |
| Augmentation in the treatment of restless legs syndrome with transdermal rotigotine. | Sleep medicine 20120601 |
| Drug safety evaluation of rotigotine. | Expert opinion on drug safety 20120501 |
| Steady-state plasma concentration profile of transdermal rotigotine: an integrated analysis of three, open-label, randomized, phase I multiple dose studies. | Clinical therapeutics 20120401 |
| Transdermal rotigotine causes impulse control disorders in patients with restless legs syndrome. | Parkinsonism & related disorders 20120201 |
| Breakthrough symptoms during the daytime in patients with restless legs syndrome (Willis-Ekbom disease). | Sleep medicine 20120201 |
| Single dose pharmacokinetics of the transdermal rotigotine patch in patients with impaired renal function. | British journal of clinical pharmacology 20120101 |
| Outcomes from switching from rotigotine patch to alternate therapies in Parkinson's disease. | The International journal of neuroscience 20120101 |
| The impact of rotigotine on cardiovascular autonomic function in early Parkinson's disease. | European neurology 20120101 |
| Spotlight on rotigotine transdermal patch in Parkinson's disease. | Drugs & aging 20111201 |
| Safety and efficacy of rotigotine in individuals with Parkinson's disease aged 75 and older. | Journal of the American Geriatrics Society 20111201 |
| Rotigotine transdermal patch in combination therapy for Parkinson's disease--observations in routine clinical practice. | Current medical research and opinion 20111001 |
| Effect of rotigotine on sleep and quality of life in Parkinson's disease patients: post hoc analysis of RECOVER patients who were symptomatic at baseline. | Expert opinion on pharmacotherapy 20110901 |
| Long-term safety and efficacy of rotigotine transdermal patch for moderate-to-severe idiopathic restless legs syndrome: a 5-year open-label extension study. | The Lancet. Neurology 20110801 |
| Another dopamine agonist for treatment of restless legs syndrome. | The Lancet. Neurology 20110801 |
| Rotigotine transdermal patch: a review of its use in the treatment of Parkinson's disease. | CNS drugs 20110801 |
| Rotigotine-induced nail dyschromia in a patient with Parkinson disease. | Neurology 20110503 |
| Hypersexuality and compulsive over-eating associated with transdermal dopamine agonist therapy. | Parkinsonism & related disorders 20110501 |
| Rotigotine effects on early morning motor function and sleep in Parkinson's disease: a double-blind, randomized, placebo-controlled study (RECOVER). | Movement disorders : official journal of the Movement Disorder Society 20110101 |
| Agonist-specific voltage sensitivity at the dopamine D2S receptor--molecular determinants and relevance to therapeutic ligands. | Neuropharmacology 20110101 |
| Cutaneous reactions to transdermal therapeutic systems. | Dermatitis : contact, atopic, occupational, drug 20110101 |
| 'You never told me I would turn into a gambler': a first person account of dopamine agonist--induced gambling addiction in a patient with restless legs syndrome. | BMJ case reports 20110101 |
| Rotigotine transdermal system for control of early morning motor impairment and sleep disturbances in patients with Parkinson's disease. | Journal of neural transmission (Vienna, Austria : 1996) 20101201 |
| Rotigotine transdermal patch in moderate to severe idiopathic restless legs syndrome: a randomized, placebo-controlled polysomnographic study. | Sleep medicine 20101001 |
| High compliance with rotigotine transdermal patch in the treatment of idiopathic Parkinson's disease. | Parkinsonism & related disorders 20100901 |
| Rotigotine improves restless legs syndrome: a 6-month randomized, double-blind, placebo-controlled trial in the United States. | Movement disorders : official journal of the Movement Disorder Society 20100815 |
| Transdermal rotigotine for the perioperative management of Parkinson's disease. | Journal of neural transmission (Vienna, Austria : 1996) 20100701 |
| Rotigotine transdermal patch for the treatment of Parkinson's disease and restless legs syndrome. | Drugs of today (Barcelona, Spain : 1998) 20100701 |
| [Pharmacology sheet. Transdermal Rotigotine (Neupro)]. | Journal de pharmacie de Belgique 20100601 |
| Treating restless legs syndrome with rotigotine. | British journal of hospital medicine (London, England : 2005) 20100401 |
| Rotigotine transdermal delivery for the treatment of restless legs syndrome. | Expert opinion on pharmacotherapy 20100301 |
| Comparing different salt forms of rotigotine to improve transdermal iontophoretic delivery. | European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 20100201 |
| Continuous rotigotine administration reduces dyskinesia resulting from pulsatile treatment with rotigotine or L-DOPA in MPTP-treated common marmosets. | Experimental neurology 20100101 |
| Rotigotine adverse effects affecting patient's sexual partner. | Clinical neuropharmacology 20100101 |
| The concept of continuous dopaminergic stimulation: what we should consider when starting Parkinson's disease treatment. | Neuro-degenerative diseases 20100101 |
| Rotigotine transdermal patch in the management of Parkinson's disease (PD) and its night-time use for PD-related sleep disorders. | Functional neurology 20100101 |
| [Continuous dopaminergic stimulation - clinical experience]. | Neurologia i neurochirurgia polska 20100101 |
| Treatment of moderate to severe restless legs syndrome: 2-year safety and efficacy of rotigotine transdermal patch. | BMC neurology 20100101 |
| Night-time use of rotigotine in advanced Parkinson's disease. | Functional neurology 20100101 |
| Dopamine dysregulation syndrome in a patient with early onset Parkinsonism and Parkin gene mutations. | Movement disorders : official journal of the Movement Disorder Society 20091215 |
| Transdermal rotigotine: a clinically innovative dopamine-receptor agonist for the management of Parkinson's disease. | Pharmacotherapy 20091201 |
| Absorption, disposition, metabolic fate, and elimination of the dopamine agonist rotigotine in man: administration by intravenous infusion or transdermal delivery. | Drug metabolism and disposition: the biological fate of chemicals 20091001 |
| Continuous administration of rotigotine to MPTP-treated common marmosets enhances anti-parkinsonian activity and reduces dyskinesia induction. | Experimental neurology 20091001 |
| Rotigotine and restless legs syndrome: new indication. The worst dopamine agonist. Just as unsatisfactory; defective design. | Prescrire international 20091001 |
| Lack of pharmacokinetic interactions between transdermal rotigotine and oral levodopa/carbidopa. | Journal of clinical pharmacology 20090901 |
| Influence of transdermal rotigotine on ovulation suppression by a combined oral contraceptive. | British journal of clinical pharmacology 20090901 |
| Rotigotine for restless legs syndrome. | Drugs of today (Barcelona, Spain : 1998) 20090901 |
| Enantiospecific binding of Rotigotine and its antipode to serum albumins: Investigation of binding constants and binding sites by partial-filling ACE. | Electrophoresis 20090801 |
| Pramipexole induced compulsive behaviors abate after initiation of rotigitine. | Movement disorders : official journal of the Movement Disorder Society 20090515 |
| Rotigotine transdermal delivery for the treatment of Parkinson's disease. | Expert opinion on pharmacotherapy 20090301 |
| Transdermal dopaminergic stimulation with rotigotine in Parkinsonian akinetic crisis. | Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 20090201 |
| Influence of domperidone on pharmacokinetics, safety and tolerability of the dopamine agonist rotigotine. | British journal of clinical pharmacology 20090201 |
| Cardiac and noncardiac fibrotic reactions caused by ergot-and nonergot-derived dopamine agonists. | Movement disorders : official journal of the Movement Disorder Society 20090115 |
| The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson's disease. | Naunyn-Schmiedeberg's archives of pharmacology 20090101 |
| Impulse control disorders arising in 3 patients treated with rotigotine. | Clinical neuropharmacology 20090101 |
| High doses of rotigotine transdermal patch: results of an open-label, dose-escalation trial in patients with advanced-stage, idiopathic Parkinson disease. | Clinical neuropharmacology 20090101 |
| Sleep attack associated to rotigotine. | Clinical neuropharmacology 20090101 |
| Biperiden enhances L-DOPA methyl ester and dopamine D(l) receptor agonist SKF-82958 but antagonizes D(2)/D(3) receptor agonist rotigotine antihemiparkinsonian actions. | European journal of pharmacology 20081203 |
| One year open-label safety and efficacy trial with rotigotine transdermal patch in moderate to severe idiopathic restless legs syndrome. | Sleep medicine 20081201 |
| Thorough QT/QTc study in patients with advanced Parkinson's disease: cardiac safety of rotigotine. | Clinical pharmacology and therapeutics 20081101 |
| Crystallisation within transdermal rotigotine patch: is there cause for concern? | Expert opinion on drug delivery 20081101 |
| Continuous versus pulsatile administration of rotigotine in 6-OHDA-lesioned rats: contralateral rotations and abnormal involuntary movements. | Journal of neural transmission (Vienna, Austria : 1996) 20081001 |
| Restless legs syndrome sees the light of day. | The Lancet. Neurology 20080701 |
| Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomised, double-blind, placebo-controlled trial. | The Lancet. Neurology 20080701 |
| Rotigotine transdermal system for the treatment of Parkinson's disease. | Clinical therapeutics 20080501 |
| Simultaneous enantioseparation of antiparkinsonian medication Rotigotine and related chiral impurities by capillary zone electrophoresis using dual cyclodextrin system. | Journal of pharmaceutical and biomedical analysis 20080414 |
| Continuous stimulation of dopaminergic receptors by rotigotine does not interfere with the sleep-wake cycle in the rat. | European journal of pharmacology 20080414 |
| New drug update: 2007. | The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists 20080401 |
| Efficacy of rotigotine transdermal system in severe restless legs syndrome: a randomized, double-blind, placebo-controlled, six-week dose-finding trial in Europe. | Sleep medicine 20080301 |
| [Rotigotine in the treatment of Parkinson's disease. A study on a sample of 150 patients]. | Revista de neurologia 20080301 |
| Neuroprotective effects of rotigotine in the acute MPTP-lesioned mouse model of Parkinson's disease. | Neuroscience letters 20080213 |
| Constant dopaminergic stimulation by transdermal delivery of dopaminergic drugs: a new treatment paradigm in Parkinson's disease. | European journal of neurology 20080101 |
| Parkinson's disease and movement disorders: moving forward. | The Lancet. Neurology 20080101 |
| Spotlight on rotigotine in Parkinson's disease. | Drugs & aging 20080101 |
| [Restless-legs syndrome]. | Revue neurologique 20080101 |
| Rotigotine transdermal patch: in restless legs syndrome. | CNS drugs 20080101 |
| Sleep disorders and neuromuscular diseases. | Reviews in neurological diseases 20080101 |
| Rotigotine transdermal patch in early Parkinson's disease: a randomized, double-blind, controlled study versus placebo and ropinirole. | Movement disorders : official journal of the Movement Disorder Society 20071201 |
| Notice of redundant publication: 'Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson disease' (Arch Neurol. 2007;64[5]:676-682). | Archives of neurology 20071201 |
| Transdermal rotigotine (Neupro) for Parkinson's disease. | The Medical letter on drugs and therapeutics 20070827 |
| Transdermal therapy in Parkinson's disease. | The Lancet. Neurology 20070601 |
| Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. | The Lancet. Neurology 20070601 |
| Rotigotine transdermal patch in the treatment of Parkinson's disease and restless legs syndrome. | Expert opinion on pharmacotherapy 20070601 |
| Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson disease. | Archives of neurology 20070501 |
| Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study. | Neurology 20070417 |
| Transdermal rotigotine: a new non-ergot dopamine agonist for the treatment of Parkinson's disease. | Expert opinion on drug delivery 20070301 |
| Plasma levels of rotigotine and the reversal of motor deficits in MPTP-treated primates. | Behavioural pharmacology 20070301 |
| The use of transdermal rotigotine in a patient with advanced Parkinson's disease and dysphagia. | Palliative medicine 20070301 |
| Rotigotine treatment partially protects from MPTP toxicity in a progressive macaque model of Parkinson's disease. | Experimental neurology 20070201 |
| Rotigotine transdermal system for perioperative administration. | Journal of neural transmission (Vienna, Austria : 1996) 20070201 |
| Rotigotine: transdermal dopamine agonist treatment of Parkinson's disease and restless legs syndrome. | The Annals of pharmacotherapy 20070201 |
| Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. | Neurology 20070123 |
| Determination of the dopamine agonist rotigotine in microdialysates from the rat brain by microbore column liquid chromatography with electrochemical detection. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070101 |
| Continuous delivery of rotigotine decreases extracellular dopamine suggesting continuous receptor stimulation. | Journal of neural transmission (Vienna, Austria : 1996) 20070101 |
| [Transdermal drugs in neurology]. | Neurologia (Barcelona, Spain) 20070101 |
| New drugs: retapamulin, bismuth subcitrate potassium, and rotigotine. | Journal of the American Pharmacists Association : JAPhA 20070101 |
| Transdermal administration of radiolabelled [14C]rotigotine by a patch formulation: a mass balance trial. | Clinical pharmacokinetics 20070101 |
| Overnight switch from oral dopaminergic agonists to transdermal rotigotine patch in subjects with Parkinson disease. | Clinical neuropharmacology 20070101 |
| Rotigotine transdermal patch: a review of its use in the management of Parkinson's disease. | CNS drugs 20070101 |
| Antidepressant properties of rotigotine in experimental models of depression. | European journal of pharmacology 20061024 |
| Rotigotine for the treatment of Parkinson's disease. | Expert review of neurotherapeutics 20060901 |
| [Transdermal rotigotine as monotherapy for Parkinson disease]. | Medizinische Monatsschrift fur Pharmazeuten 20060601 |
| Rotigotine: a novel dopamine agonist for the transdermal treatment of Parkinson's disease. | Drugs of today (Barcelona, Spain : 1998) 20060101 |
| Rotigotine transdermal patch enables rapid titration to effective doses in advanced-stage idiopathic Parkinson disease: subanalysis of a parallel group, open-label, dose-escalation study. | Clinical neuropharmacology 20060101 |
| Clinical studies with transdermal rotigotine in early Parkinson's disease. | Neurology 20050726 |
| A novel dopamine agonist for the transdermal treatment of Parkinson's disease. | Neurology 20050726 |
| A promising new technology for Parkinson's disease. | Neurology 20050726 |
| Safety, tolerability, and efficacy of continuous transdermal dopaminergic stimulation with rotigotine patch in early-stage idiopathic Parkinson disease. | Clinical neuropharmacology 20050101 |
| Rotigotine: in Parkinson's disease. | CNS drugs 20050101 |
| Rotigotine: a viewpoint by Peter LeWitt. | CNS drugs 20050101 |
| Rotigotine: a viewpoint by Tomislav Babic. | CNS drugs 20050101 |
| Patch application of the dopamine agonist rotigotine to patients with moderate to advanced stages of restless legs syndrome: a double-blind, placebo-controlled pilot study. | Movement disorders : official journal of the Movement Disorder Society 20041201 |
| Transdermal iontophoresis of rotigotine across human stratum corneum in vitro: influence of pH and NaCl concentration. | Pharmaceutical research 20040501 |
| Transdermal iontophoresis of rotigotine: influence of concentration, temperature and current density in human skin in vitro. | Journal of controlled release : official journal of the Controlled Release Society 20040416 |
| A controlled trial of rotigotine monotherapy in early Parkinson's disease. | Archives of neurology 20031201 |
| Skin penetration and mechanisms of action in the delivery of the D2-agonist rotigotine from surfactant-based elastic vesicle formulations. | Pharmaceutical research 20031001 |
| Rotigotine Schwarz Pharma. | IDrugs : the investigational drugs journal 20030901 |
| Restless legs syndrome. | The New England journal of medicine 20030821 |
| Non-oral drug delivery in Parkinson's disease: a summary from the symposium at the 7th International Congress of Parkinson's Disease and Movement Disorders. 10-14 November 2002, Miami, FL, USA. | Expert opinion on pharmacotherapy 20030401 |
| Orally active analogues of the dopaminergic prodrug 6-(N,N-di-n-propylamino)-3,4,5,6,7,8-hexahydro-2H-naphthalen-1-one: synthesis and pharmacological activity. | Journal of medicinal chemistry 20030213 |
| Further characterization of structural requirements for ligands at the dopamine D(2) and D(3) receptor: exploring the thiophene moiety. | Journal of medicinal chemistry 20020704 |
| Transdermal dopaminergic D(2) receptor agonist therapy in Parkinson's disease with N-0923 TDS: a double-blind, placebo-controlled study. | Movement disorders : official journal of the Movement Disorder Society 20010501 |
| Continuous transdermal dopaminergic stimulation in advanced Parkinson's disease. | Clinical neuropharmacology 20010101 |
| Affinity for dopamine D2, D3, and D4 receptors of 2-aminotetralins. Relevance of D2 agonist binding for determination of receptor subtype selectivity. | Journal of medicinal chemistry 19961011 |
| Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1. | Nature 19910418 |